Orchard Therapeutics Plc (ORTX) Tops Q4 EPS by 15c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q4 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $7 million versus the consensus estimate of $5.31 million.

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c